20:34 , Jul 14, 2017 |  BioCentury  |  Strategy

Back to Ipsen’s roots

After spending the last six years plugging revenue holes via licensing and M&A, Ipsen Group is once again on track to meet the 2020 financial targets it set at the beginning of the decade. But...
08:00 , Feb 29, 2016 |  BC Week In Review  |  Company News

Ipsen, 3B Pharmaceuticals deal

3B granted Ipsen exclusive, worldwide rights to develop and commercialize radiopharmaceuticals targeting the neurotensin (NTS) receptor. Ipsen will develop the preclinical compounds to treat pancreatic adenocarcinoma and potentially other cancers. 3B will receive an...